Physician profile

Gary V Hoss

Internal Medicine · Garland, TX

NPI 1083642714

$333.29

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$46.84

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $100.91 2019-2023 Wegovy
Dexcom, INC. $68.79 2020-2023 Dexcom G6 Transmitter
Abbvie INC. $37.21 2022-2023
Astrazeneca Pharmaceuticals LP $36.17 2019-2020
Novartis Pharmaceuticals Corporation $20.99 2019
Lilly USA, LLC $20.88 2022
Glaxosmithkline, LLC. $20.47 2022
Abbott Laboratories $14.27 2022
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $13.60 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gary V Hoss

$333.29

in general payments reported 2019-2025

Years
2019-2023
Top company
Novo Nordisk INC

https://glasscript.com/doctor/321520/gary-v-hoss

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.